Skip to main content

Latest oncology news

15-02-2019 | Prostate cancer | News | Article

Further support for [177Lu]-PSMA-617 in men with mCRPC

Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.

15-02-2019 | Prostate cancer | News | Article

Real-world data confirm better mCRPC OS with hormonal therapy in Black versus White men

An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.

14-02-2019 | Prostate cancer | News | Article

Long-term data support SBRT for low-, intermediate-risk prostate cancer

Stereotactic body radiotherapy has a favorable long-term disease control and safety profile in the setting of low- or intermediate-risk prostate cancer, say US researchers who analyzed individual patient data from over 2000 prospectively treated men.

13-02-2019 | Oncology | Highlight | Article

Immune checkpoint inhibitors viable in advanced cancer complicated by HIV

Immune checkpoint inhibitor therapy is well tolerated by patients with HIV infection and advanced-stage cancer and does not appear to adversely affect HIV viral load or CD4 cell count, suggest results of a systematic data review.

12-02-2019 | Prostate cancer | News | Article

Conservative management of low-risk prostate cancer increasing in USA

US patients with low-risk localized prostate cancer are increasingly being managed with active surveillance or watchful waiting, finds a database analysis.

11-02-2019 | Oncology | News | Article

ART-conceived children not at increased risk for cancer

Children conceived using assisted reproductive technology do not have an increased cancer risk relative to either the general population or naturally conceived children of women with impaired fertility, shows a Dutch study with a long follow-up.

07-02-2019 | Prostate cancer | News | Article

Adding docetaxel to ADT for high-risk nonmetastatic prostate cancer questioned

Supplementing androgen deprivation therapy with docetaxel does not appear to improve the outcomes of men with high-risk nonmetastatic prostate cancer and rising prostate-specific antigen levels after treatment, indicate phase III trial findings.

07-02-2019 | Breast cancer | News | Article

Celecoxib may be contraindicated for some breast cancer patients

Use of the cyclooxygenase 2 inhibitor celecoxib during neoadjuvant taxane-based chemotherapy is associated with adverse survival outcomes in certain subgroups of patients with breast cancer, shows a post-hoc analysis of the REMAGUS02 trial.

04-02-2019 | Prostate cancer | News | Article

Time to prostate cancer surgery does not affect outcomes in higher-risk patients

Modest differences in the time from diagnosis to radical prostatectomy do not appear to affect the outcomes of men with high- or very-high-risk prostate cancer, say the authors of a chart review.

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

01-02-2019 | Oncology | News | Article

CHEK2 pinpointed as a testicular cancer susceptibility gene

Inherited pathogenic variants in the DNA repair gene CHEK2 are associated with an increased risk for developing testicular germ cell tumors, findings indicate.

31-01-2019 | Lung cancer | News | Article

Lung cancer OS benefit with patient-reported symptom monitoring

A web-based patient-reported system for monitoring symptoms after treatment for lung cancer is associated with significantly better overall survival than standard scheduled imaging, trial results show.

31-01-2019 | Oncology | News | Article

Immune-related AEs linked to PD-1 inhibitor efficacy

The development of immune-related adverse events is associated with better outcomes in response to programmed cell death protein 1 inhibitor monotherapy across a range of tumour types, suggests a chart review.

30-01-2019 | Non-small-cell lung cancer | News | Article

MET copy number gain insignificant for TKI response in EGFR-positive NSCLC

The level of mesenchymal epithelial transition factor copy number gain does not affect response to tyrosine kinase inhibitors in patients with metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer, research shows.

29-01-2019 | Prostate cancer | News | Article

GnRH agonists, orchiectomy linked to increased risk for non-Alzheimer’s dementia

A population-based study has not replicated the previously reported association between Alzheimer’s dementia and androgen deprivation therapy, but suggests that the risk for non-Alzheimer’s dementia may be elevated with use of gonadotropin-releasing hormone agonists and orchiectomy.

25-01-2019 | Oncology | News | Article

Hepatitis screening “may be warranted” following cancer diagnosis

The prevalence of hepatitis B virus and hepatitis C virus infection in patients with newly diagnosed cancer is similar to that of the US population, but a “substantial proportion” of patients are unaware of their infection, research shows.

24-01-2019 | Kidney cancer | News | Article

HRQoL greater with nivolumab plus ipilimumab than sunitinib in advanced RCC

Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.

24-01-2019 | Breast cancer | News | Article

TILs linked to HER2-positive breast cancer treatment outcomes

Tumour-infiltrating lymphocytes could serve as a prognostic marker in patients with early-stage HER2-positive breast cancer being treated with chemotherapy plus trastuzumab, indicates an analysis of the ShortHER trial comparing 9 weeks of trastuzumab with the standard 1-year regimen.

22-01-2019 | Oncology | News | Article

Mutational load predicts immunotherapy response across most tumor types

Tumor mutational burden could be a cross-tumor predictive biomarker of immunotherapy, say US researchers who found an association between mutational load and survival across a wide range of malignancies treated with immune checkpoint inhibitors.

21-01-2019 | Kidney cancer | News | Article

Sustained benefit of VEGFR–TKIs after doublet immunotherapy in metastatic RCC

Second-line treatment with vascular endothelial growth factor receptor–tyrosine kinase inhibitors after failure of nivolumab plus ipilimumab continues to benefit patients with metastatic renal cell carcinoma, report researchers.

image credits